Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter.

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® (CT-P42, aflibercept), a biosimilar to Eylea® to ...

In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected ...

The best way to beat persistent inflation is to invest in businesses unaffected by rising prices, like these four high-yield ...

CJ Bioscience announced today that it will present preclinical data on its novel drug candidate CJRB-201 at the European ...

Systemic circulation of chemotherapy drugs leads to off-target side effects, premature drug loss, and limited therapeutic ...

Furin is identified as the key enzyme responsible for cleaving the apelin precursor. Inhibiting this cleavage could serve as ...

Saltability, a Himalayan salt wellness product supplier, has developed a new Mini Massage Kit to provide a soothing spa experience both for professionals and at-home users. The set features a ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...